Key result
Sirolimus-coated balloons reduce late lumen loss by ~0.11 mm vs. paclitaxel-coated balloons in coronary ISR.
Why the study?
In-stent restenosis remains a major limitation of PCI, and recent generations of sirolimus-coated balloons may offer improved outcomes compared to paclitaxel-coated balloons.
Do sirolimus-coated balloons improve angiographic and clinical outcomes compared to paclitaxel-coated balloons in patients with coronary in-stent restenosis?
Meta-Analysis (n=3,240)
Yes
Do sirolimus-coated balloons improve angiographic and clinical outcomes compared to paclitaxel-coated balloons in patients with coronary in-stent restenosis?
Sirolimus-coated balloons provide superior angiographic outcomes (lower late lumen loss) and comparable clinical safety compared to paclitaxel-coated balloons for treating coronary in-stent restenosis.
Answers are grounded in this paper and cite their sources.
Sirolimus-coated balloons merit consideration over paclitaxel-coated balloons for coronary in-stent restenosis; extends meta-analytic support for sirolimus platforms.
Background In-stent restenosis (ISR) remains a major limitation of percutaneous coronary intervention (PCI), even in the drug-eluting stent era. Drug-eluting balloons (DEB) have emerged as an alternative to repeat stenting by providing homogeneous antiproliferative drug delivery without additional metal layers. Recent generations of sirolimus-coated balloons (SCB) may offer improved outcomes compared to paclitaxel-coated balloons (PCB). Methods A systematic search was conducted in PubMed, Embase, and Scopus databases for studies published between January 2020 and October 2025 comparing SCB and PCB in the treatment of ISR. Primary endpoints included late lumen loss (LLL) and binary restenosis. Secondary endpoints were target lesion revascularization (TLR) and major adverse cardiac events (MACE). Data extraction and quality assessment followed PRISMA guidelines, and pooled analysis was performed using a random-effects model. Results Eleven studies with a total of 3240 patients met inclusion criteria. SCB demonstrated significantly lower LLL (mean difference −0.11 mm; P = 0.02) and a trend toward reduced TLR (OR 0.78; 95% CI 0.59–1.02). No significant difference was observed in MACE or mortality between groups. Study heterogeneity was low for most endpoints (I2 < 35%). Conclusions Sirolimus-coated balloons appear to provide superior angiographic outcomes and comparable safety compared to paclitaxel-coated balloons in ISR management. Further large-scale randomized trials with long-term follow-up are warranted to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Abdullah Youssef (2026) conducted a meta-analysis in Coronary in-stent restenosis (ISR) (n=3,240). Sirolimus-coated balloons (SCB) vs. Paclitaxel-coated balloons (PCB) was evaluated on Late lumen loss (LLL) and binary restenosis (MD -0.11 mm, p=0.02). Sirolimus-coated balloons reduced late lumen loss compared to paclitaxel-coated balloons in patients with coronary in-stent restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: